Abstract
RATIONALE: Interstitial lung disease (ILD) is one of the major organ involvements associated with dermatomyositis and polymyositis (DM/PM), and it often affects the patient's survival. Glucocorticoid alone has been shown to be insufficient even as an initial treatment for this manifestation, especially when anti-aminoacyl tRNA synthetase antibodies are present. We examined the efficacy of a lower dose of tacrolimus and the usefulness of KL-6 as a disease surrogate marker.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
